Q1 2026 Evogene Ltd Earnings Call Transcript
Key Points
- Evogene Ltd (EVGN) has made significant progress in its core technology platform, ChemPass AI, with a second collaboration with Google to enhance AI capabilities.
- The company has established strategic collaborations in the pharmaceutical sector, including partnerships with Systasy Bioscience and Ludwig Maximilian University Hospital, focusing on unmet medical needs.
- Evogene Ltd (EVGN) has a growing pipeline in its Pharma division, with new collaborations targeting significant markets such as neurodegenerative disorders and chemotherapy resistance.
- The company's subsidiary, AgPlenus, is advancing its internal project on a new fungicide for Septoria, addressing a major market need in agriculture.
- Evogene Ltd (EVGN) is actively pursuing strategic collaborations and partnerships across its business areas, positioning itself for sustained growth and long-term success.
- Evogene Ltd (EVGN) reported a net loss of approximately $5.9 million for the first quarter of 2026, an increase from the previous year.
- The company's revenues for the first quarter of 2026 decreased significantly to approximately $0.3 million from $2.3 million in the same period of 2025.
- The collaboration with Bayer in the ag chemical sector was terminated due to issues with the biology of the target protein, impacting potential developments.
- Evogene Ltd (EVGN) is facing challenges in convincing big pharma companies to adopt its technology, which may delay significant transactions and equity investments.
- The company has discontinued or significantly scaled down activities in subsidiaries like Lavie Bio and Biomica, reflecting a strategic shift but also a reduction in operational scope.
Welcome to Evogene's first-quarter 2026 results conference call. (Operator Instructions) As a reminder, this conference is being recorded May 20, 2026.
Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events and Evogene Ltd., the company, may, from time to time, make other statements regarding our outlook or expectation for future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995, the PSLRA and other securities laws as amended.
Statements that are not statements of historical facts may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should, plan, estimated, intend and potential or words of similar meaning.
We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
